Large drugmakers to be active in R&D

Domestic big pharmaceutical firms are expected to focus on their research and development (R&D) sector this year in an attempt to cope with a new harsh environments involving the FTA and the government's new drug pricing policy, so-called "positive list system, according to pharmaceutical business sources.

"Pharmaceutical firm should strive to develop their independent generic formulation te...